BACKGROUND AND AIMS: Estimates have been made concerning the fraction of colorectal cancer (CRC) cases that meet Amsterdam I criteria but not Amsterdam II criteria. The aim of this study was to determine in a population setting what fraction of CRC cases can be considered familial high-risk, what fraction of these meet Amsterdam I or II criteria, and what fraction of CRC cases overall meet Amsterdam I and II criteria. METHODS: The Utah Population Data Base (UPDB), which links Utah genealogies to the Utah Cancer Registry, was used to examine the aims of the study. Familial high-risk was operationally defined as CRC occurring at an age <50 years or as a part of a first-degree relative pair. A subset of Amsterdam positive cancers was tested for microsatellite instability (MSI) to determine what fraction of Amsterdam families was likely to have hereditary nonpolyposis colorectal cancer (HNPCC). RESULTS: Of the 6,628 CRC cases in the UPDB, 24.5% met the criteria for familial high-risk. Of these, 2.6% met Amsterdam I criteria and 5.5% Amsterdam II. Of total data base CRC cases, 0.8% met Amsterdam I criteria and 2.3% Amsterdam II. In a subset of colon tumors from Amsterdam families, 70% were MSI stable. CONCLUSIONS: Although nearly 25% of CRC cases in our population data base met a simple definition of familial high-risk, only a small fraction of these and a smaller fraction of total CRC cases met Amsterdam I or II criteria. Less than half of a limited set of tumors from Amsterdam families were MSI positive.
BACKGROUND AND AIMS: Estimates have been made concerning the fraction of colorectal cancer (CRC) cases that meet Amsterdam I criteria but not Amsterdam II criteria. The aim of this study was to determine in a population setting what fraction of CRC cases can be considered familial high-risk, what fraction of these meet Amsterdam I or II criteria, and what fraction of CRC cases overall meet Amsterdam I and II criteria. METHODS: The Utah Population Data Base (UPDB), which links Utah genealogies to the Utah Cancer Registry, was used to examine the aims of the study. Familial high-risk was operationally defined as CRC occurring at an age <50 years or as a part of a first-degree relative pair. A subset of Amsterdam positive cancers was tested for microsatellite instability (MSI) to determine what fraction of Amsterdam families was likely to have hereditary nonpolyposis colorectal cancer (HNPCC). RESULTS: Of the 6,628 CRC cases in the UPDB, 24.5% met the criteria for familial high-risk. Of these, 2.6% met Amsterdam I criteria and 5.5% Amsterdam II. Of total data base CRC cases, 0.8% met Amsterdam I criteria and 2.3% Amsterdam II. In a subset of colon tumors from Amsterdam families, 70% were MSI stable. CONCLUSIONS: Although nearly 25% of CRC cases in our population data base met a simple definition of familial high-risk, only a small fraction of these and a smaller fraction of total CRC cases met Amsterdam I or II criteria. Less than half of a limited set of tumors from Amsterdam families were MSI positive.
Authors: W S Samowitz; K Curtin; H H Lin; M A Robertson; D Schaffer; M Nichols; K Gruenthal; M F Leppert; M L Slattery Journal: Gastroenterology Date: 2001-10 Impact factor: 22.682
Authors: P Lichtenstein; N V Holm; P K Verkasalo; A Iliadou; J Kaprio; M Koskenvuo; E Pukkala; A Skytthe; K Hemminki Journal: N Engl J Med Date: 2000-07-13 Impact factor: 91.245
Authors: C R Boland; S N Thibodeau; S R Hamilton; D Sidransky; J R Eshleman; R W Burt; S J Meltzer; M A Rodriguez-Bigas; R Fodde; G N Ranzani; S Srivastava Journal: Cancer Res Date: 1998-11-15 Impact factor: 12.701
Authors: C M Lewis; S L Neuhausen; D Daley; F J Black; J Swensen; R W Burt; L A Cannon-Albright; M H Skolnick Journal: Cancer Res Date: 1996-03-15 Impact factor: 12.701
Authors: Asad Umar; C Richard Boland; Jonathan P Terdiman; Sapna Syngal; Albert de la Chapelle; Josef Rüschoff; Richard Fishel; Noralane M Lindor; Lawrence J Burgart; Richard Hamelin; Stanley R Hamilton; Robert A Hiatt; Jeremy Jass; Annika Lindblom; Henry T Lynch; Païvi Peltomaki; Scott D Ramsey; Miguel A Rodriguez-Bigas; Hans F A Vasen; Ernest T Hawk; J Carl Barrett; Andrew N Freedman; Sudhir Srivastava Journal: J Natl Cancer Inst Date: 2004-02-18 Impact factor: 13.506
Authors: Randall W Burt; Mark F Leppert; Martha L Slattery; Wade S Samowitz; Lisa N Spirio; Richard A Kerber; Scott K Kuwada; Deborah W Neklason; James A Disario; Elaine Lyon; J Preston Hughes; William Y Chey; Raymond L White Journal: Gastroenterology Date: 2004-08 Impact factor: 22.682
Authors: Deborah W Neklason; Thérèse M Tuohy; Jeffery Stevens; Brith Otterud; Lisa Baird; Richard A Kerber; Wade S Samowitz; Scott K Kuwada; Mark F Leppert; Randall W Burt Journal: J Med Genet Date: 2010-06-03 Impact factor: 6.318
Authors: Deborah W Neklason; Brett L Thorpe; Angel Ferrandez; Anil Tumbapura; Kenneth Boucher; Gilda Garibotti; Richard A Kerber; Cindy H Solomon; Wade S Samowitz; John C Fang; Geraldine P Mineau; Mark F Leppert; Randall W Burt; Scott K Kuwada Journal: Am J Gastroenterol Date: 2008-07-30 Impact factor: 10.864
Authors: Jamie L McCall; Drew Gehring; Beth K Clymer; Kurt W Fisher; Binita Das; David L Kelly; Hyunseok Kim; Michael A White; Robert E Lewis Journal: Mol Cell Biol Date: 2016-08-12 Impact factor: 4.272
Authors: Anita Y Kinney; Watcharaporn Boonyasiriwat; Scott T Walters; Lisa M Pappas; Antoinette M Stroup; Marc D Schwartz; Sandra L Edwards; Amy Rogers; Wendy K Kohlmann; Kenneth M Boucher; Sally W Vernon; Rebecca G Simmons; Jan T Lowery; Kristina Flores; Charles L Wiggins; Deirdre A Hill; Randall W Burt; Marc S Williams; John C Higginbotham Journal: J Clin Oncol Date: 2014-01-21 Impact factor: 44.544
Authors: R C Green; J S Green; S K Buehler; J D Robb; D Daftary; S Gallinger; J R McLaughlin; P S Parfrey; H B Younghusband Journal: Fam Cancer Date: 2007 Impact factor: 2.375